Victory Capital Management Inc. Has $13.13 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 10.5% during the first quarter, Holdings Channel reports. The institutional investor owned 72,815 shares of the company’s stock after selling 8,513 shares during the quarter. Victory Capital Management Inc.’s holdings in Krystal Biotech were worth $13,129,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $95,000. Covestor Ltd increased its position in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after purchasing an additional 642 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after purchasing an additional 432 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $223,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on KRYS shares. Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Citigroup reiterated a “neutral” rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. HC Wainwright reiterated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. Chardan Capital reiterated a “buy” rating and set a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $211.33.

Krystal Biotech Price Performance

KRYS stock opened at $153.25 on Thursday. The business’s fifty day moving average price is $137.53 and its two-hundred day moving average price is $155.81. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 36.84 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the company’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 49,800 shares of company stock valued at $7,487,943 in the last 90 days. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).